Fig. 01 -

Title Slide

Fig. 02 -

Disclosures

Fig. 03 -

Topics

Fig. 04 -

Objective

Fig. 05 -

DVT and PE Patient

Fig. 06 -

Case

Fig. 07 -

Anticoagulation

Fig. 08 -

Recurrence Triangle

Fig. 09 -

Recurrence Triangle (Cont.)

Fig. 10 -

"Strong" Thrombophilias

Fig. 11 -

D-Dimer and VTE

Fig. 12 -

Predictor

Fig. 13 -

Predictor (Cont.)

Fig. 14 -

Man with Unprovoked VTE

Fig. 15 -

Woman with Unprovoked VTE

Fig. 16 -

Non-major Transient Risk Factor

Fig. 17 -

"Strong" Thrombophilias (Cont.)

Fig. 18 -

Individual Thrombophilias

Fig. 19 -

Inherited and Acquired Thrombophilias

Fig. 20 -

Prevalences

Fig. 21 -

Risk of 1st VTE

Fig. 22 -

Risk of Recurrent VTE: 1-4

Fig. 23 -

Risk of Recurrent VTE: 5-6

Fig. 24 -

Deficiency

Fig. 25 -

Antiphospholipid Antibody Testing

Fig. 26 -

Antiphospholipid Antibodies

Fig. 27 -

Antibody Titer vs Time

Fig. 28 -

Sapporo/Sidney Criteria

Fig. 29 -

Practical Points

Fig. 30 -

Homocysteine, MTHFR

Fig. 31 -

Other Thrombophilias

Fig. 32 -

Influence of Anticoagulants

Fig. 33 -

Unexplained Arterial Thrombosis

Fig. 34 -

Arterial Thrombosis

Fig. 35 -

Secondary Prevention

Fig. 36 -

Whom to Test for Thrombophilia

Fig. 37 -

Whom to Test

Fig. 38 -

Whom Do I Consider

Fig. 39 -

Who and When to Test

Fig. 40 -

Whom NOT to Test

Fig. 41 -

Family Members

Fig. 42 -

What to Test?

Fig. 43 -

Inherited and Acquired (Cont.)

Fig. 44 -

DOAC Drug Level Testing

Fig. 45 -

When to Consider

Fig. 46 -

Timing

Fig. 47 -

DOAC Level Testing

Fig. 48 -

PT

Fig. 49 -

aPTT

Fig. 50 -

Anti-Xa Assay

Fig. 51 -

Thrombin Clot Time

Fig. 52 -

Ecarin Assays

Fig. 53 -

Expected Levels

Fig. 54 -

Very Obese Patient

Fig. 55 -

Intra-individual Differences

Fig. 56 -

Levels + Efficacy

Fig. 57 -

Edoxaban

Fig. 58 -

Rivaroxaban

Fig. 59 -

Apixaban

Fig. 60 -

Expected Levels (Cont.)

Fig. 61 -

Elderly, "Fragile"

Fig. 62 -

Recurrent Thrombosis

Fig. 63 -

Performance

Fig. 64 -

Summary